208 related articles for article (PubMed ID: 36071844)
1. Cell-cycle and apoptosis related and proteomics-based signaling pathways of human hepatoma Huh-7 cells treated by three currently used multi-RTK inhibitors.
Ren X; Zhang Q; Guo W; Wang L; Wu T; Zhang W; Liu M; Kong D
Front Pharmacol; 2022; 13():944893. PubMed ID: 36071844
[TBL] [Abstract][Full Text] [Related]
2. Different Mechanisms of Action of Regorafenib and Lenvatinib on Toll-Like Receptor-Signaling Pathways in Human Hepatoma Cell Lines.
Sasaki R; Kanda T; Fujisawa M; Matsumoto N; Masuzaki R; Ogawa M; Matsuoka S; Kuroda K; Moriyama M
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397371
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of sorafenib followed by regorafenib or lenvatinib in patients with hepatocellular carcinoma.
Terashima T; Yamashita T; Takata N; Takeda Y; Kido H; Iida N; Kitahara M; Shimakami T; Takatori H; Arai K; Kawaguchi K; Kitamura K; Yamashita T; Sakai Y; Mizukoshi E; Honda M; Kaneko S
Hepatol Res; 2021 Feb; 51(2):190-200. PubMed ID: 33197087
[TBL] [Abstract][Full Text] [Related]
4. Differential effectiveness of tyrosine kinase inhibitors in 2D/3D culture according to cell differentiation, p53 status and mitochondrial respiration in liver cancer cells.
Rodríguez-Hernández MA; Chapresto-Garzón R; Cadenas M; Navarro-Villarán E; Negrete M; Gómez-Bravo MA; Victor VM; Padillo FJ; Muntané J
Cell Death Dis; 2020 May; 11(5):339. PubMed ID: 32382022
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the safety and prognosis of sequential regorafenib after sorafenib and lenvatinib treatment failure in patients with unresectable hepatocellular carcinoma: a retrospective cohort study.
Zhai J; Liu J; Fu Z; Bai S; Li X; Qu Z; Sun Y; Ge R; Xue F
J Gastrointest Oncol; 2022 Jun; 13(3):1278-1288. PubMed ID: 35837155
[TBL] [Abstract][Full Text] [Related]
6. SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer.
Kim SY; Kim SM; Chang HJ; Kim BW; Lee YS; Park CS; Park KC; Chang HS
BMC Cancer; 2018 Oct; 18(1):956. PubMed ID: 30286728
[TBL] [Abstract][Full Text] [Related]
7. PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib.
Xu Y; Fu S; Shang K; Zeng J; Mao Y
Front Oncol; 2022; 12():958869. PubMed ID: 36176403
[TBL] [Abstract][Full Text] [Related]
8. [Lenvatinib down-regulates IGF1R/Mek/Erk signaling pathway in the treatment of regorafenib-resistant hepatocellular carcinoma].
Zhang J; Kuang SW; Huang N; Zhang JJ; Liu M; Wang LM
Zhonghua Zhong Liu Za Zhi; 2023 Jun; 45(6):490-498. PubMed ID: 37355467
[No Abstract] [Full Text] [Related]
9. Molecularly targeted anti-cancer drugs inhibit the invasion and metastasis of hepatocellular carcinoma by regulating the expression of MMP and TIMP gene families.
He XX; Shi LL; Qiu MJ; Li QT; Wang MM; Xiong ZF; Yang SL
Biochem Biophys Res Commun; 2018 Oct; 504(4):878-884. PubMed ID: 30219235
[TBL] [Abstract][Full Text] [Related]
10. CRISPR/Cas9 genome-wide screening identifies KEAP1 as a sorafenib, lenvatinib, and regorafenib sensitivity gene in hepatocellular carcinoma.
Zheng A; Chevalier N; Calderoni M; Dubuis G; Dormond O; Ziros PG; Sykiotis GP; Widmann C
Oncotarget; 2019 Dec; 10(66):7058-7070. PubMed ID: 31903165
[TBL] [Abstract][Full Text] [Related]
11. Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma.
Tutusaus A; Stefanovic M; Boix L; Cucarull B; Zamora A; Blasco L; de Frutos PG; Reig M; Fernandez-Checa JC; Marí M; Colell A; Bruix J; Morales A
Oncotarget; 2018 Mar; 9(24):16701-16717. PubMed ID: 29682179
[TBL] [Abstract][Full Text] [Related]
12. Synergism of small molecules targeting VDAC with sorafenib, regorafenib or lenvatinib on hepatocarcinoma cell proliferation and survival.
Ventura C; Junco M; Santiago Valtierra FX; Gooz M; Zhiwei Y; Townsend DM; Woster PM; Maldonado EN
Eur J Pharmacol; 2023 Oct; 957():176034. PubMed ID: 37652292
[TBL] [Abstract][Full Text] [Related]
13. The HDAC Inhibitor Quisinostat (JNJ-26481585) Supresses Hepatocellular Carcinoma alone and Synergistically in Combination with Sorafenib by G0/G1 phase arrest and Apoptosis induction.
He B; Dai L; Zhang X; Chen D; Wu J; Feng X; Zhang Y; Xie H; Zhou L; Wu J; Zheng S
Int J Biol Sci; 2018; 14(13):1845-1858. PubMed ID: 30443188
[TBL] [Abstract][Full Text] [Related]
14. Effect of Lenvatinib treatment on the cell cycle and microRNA profile in hepatocellular carcinoma cells.
Nakahara M; Fujihara S; Iwama H; Takuma K; Oura K; Tadokoro T; Fujita K; Tani J; Morishita A; Kobara H; Himoto T; Masaki T
Biomed Rep; 2022 Oct; 17(4):78. PubMed ID: 36158319
[TBL] [Abstract][Full Text] [Related]
15. Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma.
Lai YL; Wang KH; Hsieh HP; Yen WC
J Biomed Sci; 2022 Jan; 29(1):5. PubMed ID: 35062934
[TBL] [Abstract][Full Text] [Related]
16. Revealing the suppressive role of protein kinase C delta and p38 mitogen-activated protein kinase (MAPK)/NF-κB axis associates with lenvatinib-inhibited progression in hepatocellular carcinoma in vitro and in vivo.
Wu CH; Hsu FT; Chao TL; Lee YH; Kuo YC
Biomed Pharmacother; 2022 Jan; 145():112437. PubMed ID: 34864311
[TBL] [Abstract][Full Text] [Related]
17. Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan.
Ogasawara S; Ooka Y; Itokawa N; Inoue M; Okabe S; Seki A; Haga Y; Obu M; Atsukawa M; Itobayashi E; Mizumoto H; Sugiura N; Azemoto R; Kanayama K; Kanzaki H; Maruta S; Maeda T; Kusakabe Y; Yokoyama M; Kobayashi K; Kiyono S; Nakamura M; Saito T; Suzuki E; Nakamoto S; Yasui S; Tawada A; Chiba T; Arai M; Kanda T; Maruyama H; Kato N
Invest New Drugs; 2020 Feb; 38(1):172-180. PubMed ID: 31172442
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma.
Kissel M; Berndt S; Fiebig L; Kling S; Ji Q; Gu Q; Lang T; Hafner FT; Teufel M; Zopf D
Oncotarget; 2017 Dec; 8(63):107096-107108. PubMed ID: 29291014
[TBL] [Abstract][Full Text] [Related]
19. Comparative Response of HCC Cells to TKIs: Modified in vitro Testing and Descriptive Expression Analysis.
Sagmeister P; Daza J; Ofner A; Ziesch A; Ye L; Ben Khaled N; Ebert M; Mayerle J; Teufel A; De Toni EN; Munker S
J Hepatocell Carcinoma; 2022; 9():595-607. PubMed ID: 35845819
[TBL] [Abstract][Full Text] [Related]
20. Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades.
Hoshi T; Watanabe Miyano S; Watanabe H; Sonobe RMK; Seki Y; Ohta E; Nomoto K; Matsui J; Funahashi Y
Biochem Biophys Res Commun; 2019 May; 513(1):1-7. PubMed ID: 30944079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
